Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitute of Mountain Emergency Medicine

About this trial

The goal of this observational study is to learn whether intravenous iloprost treatment for severe frostbite (grades 3-4) is feasible and safe when delivered in pre-hospital, remote high-altitude settings.

The main questions it aims to answer are:

* Is it feasible to initiate and deliver guideline-based intravenous iloprost for grade 3-4 frostbite at high altitude and what logistical barriers arise? * Does field-based initiation of iloprost increase tissue preservation and reduce amputations (compared to historical cases from similar settings)?

Participants receiving Iloprost as part of a frostbite treatment will be followed up after discharge as well as 6, 12 and 18 months to assess tissue preservation and long-term sequelae from the initial frostbite injury.

Eligibility criteria

Qualifiers

Frostbite grade 3/4 eligible for Iloprost

<72h of thawing

min. age of 18 years

provision of written informed consent

Disqualifiers

age <18 years

general contraindication

pregnancy

inability/denial to provide informed consent

Trial design

Treatments tested in this trial

  • Iloprost (Ilomedin, BAYQ6256)

Treatment groups

No treatment groups listed